CIK 0000715446 · Non-accelerated filer<br>Smaller reporting company
Anixa Biosciences Inc
Sign in to watch- Ticker
- ANIX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Oct 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 112622630
- Phone
- 408-708-9808
- Business address
- 3150 ALMADEN EXPRESSWAY, SUITE 250, SAN JOSE, CA, 95118
- Former names
- ITUS Corp, COPYTELE INC
- 10-Q Report Quarterly Report
- DEFA14A Proxy Proxy Materials
- DEF 14A Proxy Proxy Statement
- 4 Open-market buy Director bought 4,500 shares at $3.26 ($14,670)
- 4 Open-market buy Director bought 400 shares at $3.16 ($1,264)
- 4 Open-market buy Director bought 400 shares at an average $3.52 ($1,408)
- 4 Open-market buy Director bought 900 shares at $3.31 ($2,979)
- 4 Open-market buy Director bought 500 shares at $3.60 ($1,800)
- 4 Open-market buy Director bought 2,000 shares at an average $3.36 ($6,710)
- 4 Open-market sale V.P., Finance & CFO sold 2,000 shares at an average $3.26 ($6,525)
- 4 Open-market buy Director bought 2,604 shares at an average $3.31 ($8,630)
- 10-Q Report Quarterly Report
- 4 Open-market buy Director bought 500 shares at an average $2.88 ($1,438)
- 4 Open-market buy Director bought 200 shares at $2.82 ($564)
- 4 Open-market buy Director bought 600 shares at an average $3.01 ($1,807)
- 4 Open-market buy Director bought 100 shares at $3.03 ($303)
- 4 Open-market buy Director bought 720 shares at $2.76 ($1,985)
- 4 Open-market buy Director bought 500 shares at $2.85 ($1,425)
- 4 Open-market buy Director bought 500 shares at $2.96 ($1,480)
- 4 Open-market buy Director bought 500 shares at $2.94 ($1,470)
Page 21 of 50 · 983 filings